BrightPath Biotherapeutics (4594) Stock Overview
Engages in the development of cancer immunotherapy drugs in Japan. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
4594 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
BrightPath Biotherapeutics Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥45.00 |
| 52 Week High | JP¥114.00 |
| 52 Week Low | JP¥43.00 |
| Beta | 1.26 |
| 1 Month Change | -13.46% |
| 3 Month Change | -33.82% |
| 1 Year Change | -6.25% |
| 3 Year Change | -65.65% |
| 5 Year Change | -75.27% |
| Change since IPO | -89.18% |
Recent News & Updates
Recent updates
Shareholder Returns
| 4594 | JP Biotechs | JP Market | |
|---|---|---|---|
| 7D | 2.3% | -1.2% | 4.7% |
| 1Y | -6.3% | -35.3% | 46.9% |
Return vs Industry: 4594 exceeded the JP Biotechs industry which returned -35.3% over the past year.
Return vs Market: 4594 underperformed the JP Market which returned 46.9% over the past year.
Price Volatility
| 4594 volatility | |
|---|---|
| 4594 Average Weekly Movement | 13.1% |
| Biotechs Industry Average Movement | 7.4% |
| Market Average Movement | 4.6% |
| 10% most volatile stocks in JP Market | 9.3% |
| 10% least volatile stocks in JP Market | 2.3% |
Stable Share Price: 4594's share price has been volatile over the past 3 months compared to the JP market.
Volatility Over Time: 4594's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of JP stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | n/a | Kenichi Nagai | www.brightpathbio.com |
BrightPath Biotherapeutics Co., Ltd. engages in the development of cancer immunotherapy drugs in Japan. The company is developing BP2201, a product candidate in Phase I clinical trials to target cancer antigens in various types of cancer; BP2202, Phase I clinical trial to target cancer; and BP2301, a product candidate in Phase I clinical trials for the treatment of solid tumors sarcoma and gynecological cancers. In addition, its product candidates in preclinical trials include BP1200 that targets CD73; BP1202 that targets CD39; BP1210, which suppresses T cell cytotoxicity; BP1212 to inhibit TIM-3 and CD39; BP1209 to target tumor-specific neoantigens; and BP1223 to target blood cancers.
BrightPath Biotherapeutics Co., Ltd. Fundamentals Summary
| 4594 fundamental statistics | |
|---|---|
| Market cap | JP¥6.25b |
| Earnings (TTM) | -JP¥1.29b |
| Revenue (TTM) | JP¥1.08m |
Is 4594 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4594 income statement (TTM) | |
|---|---|
| Revenue | JP¥1.08m |
| Cost of Revenue | JP¥18.00k |
| Gross Profit | JP¥1.06m |
| Other Expenses | JP¥1.29b |
| Earnings | -JP¥1.29b |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
Aug 14, 2026
| Earnings per share (EPS) | -9.30 |
| Gross Margin | 98.33% |
| Net Profit Margin | -119,884.49% |
| Debt/Equity Ratio | 0% |
How did 4594 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/21 17:20 |
| End of Day Share Price | 2026/06/19 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
BrightPath Biotherapeutics Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.